Key result
Abciximab administration during primary PCI reduced one-year mortality from 12.7% to 7.8% in STEMI patients with complex lesions, but showed no benefit in those with simple lesions.
Observational (n=2,935)
No
Answers are grounded in this paper and cite their sources.
Supports selective abciximab use in complex-lesion STEMI PCI; extends RCT evidence by identifying lesion complexity as treatment-effect modifier.
The optimal timing of abciximab administration (up-stream/in-cath-lab) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) is unclear. Data suggest that patients with high-risk profiles benefit from abciximab the most. Complex lesion on coronary angiography (CAG) implies a high-risk profile. Thus, we aimed to investigate whether lesion type (complex/simple) predicted the effect of abciximab in STEMI-patients undergoing pPCI.
No takes yet. Share an insight, caveat, or question.
Iversen et al. (2013) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=2,935). Abciximab vs. No abciximab was evaluated on All-cause mortality at 1 year (in patients with complex lesions) (HR 0.62, 95% CI 0.42-0.91, p=0.015). Abciximab administration during primary PCI reduced one-year mortality from 12.7% to 7.8% in STEMI patients with complex lesions, but showed no benefit in those with simple lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: